Literature DB >> 19043718

Antiphospholipid antibody, head-shaking and ataxia: an evidence of non-vascular neurotoxicity and successful treatment by plasmapheresis.

Wei-Hsi Chen1, Chung-Jen Chen.   

Abstract

Although antiphospholipid antibodies (APAbs) are considered to possess neurotoxic property, their relation with non-vascular neurological disorder is still disputed. This dilemma is mainly due to only a cross-sectional analysis or sporadic pictorial description in previous reports. In addition, treatment strategy is unknown in this situation. We encountered a patient who exhibited head-shaking and cerebellar ataxia had an increase of blood anti-beta2-glycoprotein I antibody and anticardiolipin antibody. Her neurological deficits did not respond to corticosteroid pulse therapy but rapidly subsided after plasmapheresis associated with a normalization of APAbs. Accordingly, a causal relation between APAbs and non-vascular neurological disorder is favored. The pathogenesis of APAb-related non-vascular neurotoxicity is warranted for further study to avoid premature conclusion. Plasmapheresis is recommended when movement disorder responds poorly to conventional treatment, especially when APAb is found.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19043718     DOI: 10.1007/s00296-008-0778-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

1.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

2.  Antiphospholipid antibodies bind to rat cerebellar granule cells: the role of N-methyl-D-aspartate receptors.

Authors:  A Riccio; C Andreassi; M L Eboli
Journal:  Neurosci Lett       Date:  1998-11-27       Impact factor: 3.046

Review 3.  Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature.

Authors:  R Cervera; R A Asherson; J Font; M Tikly; L Pallarés; A Chamorro; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  1997-05       Impact factor: 1.889

4.  Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes.

Authors:  J Chapman; M Cohen-Armon; Y Shoenfeld; A D Korczyn
Journal:  Lupus       Date:  1999       Impact factor: 2.911

5.  Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells.

Authors:  B Caronti; C Calderaro; C Alessandri; F Conti; R Tinghino; C Pini; G Palladini; G Valesini
Journal:  J Autoimmun       Date:  1998-10       Impact factor: 7.094

6.  Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer.

Authors:  Y Shoenfeld; A Nahum; A D Korczyn; M Dano; R Rabinowitz; O Beilin; C G Pick; L Leider-Trejo; L Kalashnikova; M Blank; J Chapman
Journal:  Lupus       Date:  2003       Impact factor: 2.911

7.  Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons.

Authors:  H H Liou; C R Wang; H C Chou; V L Arvanov; R C Chen; Y C Chang; C Y Chuang; C Y Chen; M C Tsai
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

Review 8.  Neurological manifestations of the antiphospholipid syndrome: risk assessments and evidence-based medicine.

Authors:  E Muscal; R L Brey
Journal:  Int J Clin Pract       Date:  2007-06-26       Impact factor: 2.503

9.  Hyperhomocysteinemia relates to the subtype of antiphospholipid antibodies in non-SLE patients.

Authors:  Wei Hsi Chen; Hung Sheng Lin; Yi Fen Kao; Min Yu Lan; Jia Shou Liu
Journal:  Clin Appl Thromb Hemost       Date:  2007-10       Impact factor: 2.389

10.  Postoperative parkinsonism and lupus anticoagulant: a model of autoantibody-mediated neurotoxicity in stress.

Authors:  Wei-Hsi Chen; Hung-Sheng Lin; Yin-Fen Kao; Min-Yu Lan; Jia-Shou Liu
Journal:  Brain Inj       Date:  2007-05       Impact factor: 2.311

  10 in total
  3 in total

1.  Cerebellar syndrome in chronic cyclic magnesium depletion.

Authors:  Luis Miguel Blasco
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

Review 2.  Movement and Other Neurodegenerative Syndromes in Patients with Systemic Rheumatic Diseases: A Case Series of 8 Patients and Review of the Literature.

Authors:  Rikitha Menezes; Alexander Pantelyat; Izlem Izbudak; Julius Birnbaum
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

3.  The association between serological biomarkers and primary Sjogren's syndrome associated with peripheral polyneuropathy.

Authors:  Che-Wei Hsu; Yu-Jih Su; Wen-Neng Chang; Nai-Wen Tsai; Wen-Chan Chiu; Ben-Chung Cheng; Chih-Min Su; Chi-Ren Huang; Ya-Ting Chang; Cheng-Hsien Lu
Journal:  Biomed Res Int       Date:  2014-04-13       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.